These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 3318454)
1. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. Knopp RH; Brown WV; Dujovne CA; Farquhar JW; Feldman EB; Goldberg AC; Grundy SM; Lasser NL; Mellies MJ; Palmer RH Am J Med; 1987 Nov; 83(5B):50-9. PubMed ID: 3318454 [TBL] [Abstract][Full Text] [Related]
2. Effect of fenofibrate treatment on plasma lipoprotein lipids, high-density lipoprotein cholesterol subfractions, and apolipoproteins B, AI, AII, and E. Knopp RH; Walden CE; Warnick GR; Albers JJ; Ginsberg J; McGinnis BM Am J Med; 1987 Nov; 83(5B):75-84. PubMed ID: 3120587 [TBL] [Abstract][Full Text] [Related]
3. Fenofibrate affects the compositions of lipoproteins. Goldberg AC; Schonfeld G; Anderson C; Dillingham MA Am J Med; 1987 Nov; 83(5B):60-5. PubMed ID: 3318455 [TBL] [Abstract][Full Text] [Related]
4. Potential use of fenofibrate and other fibric acid derivatives in the clinic. Brown WV Am J Med; 1987 Nov; 83(5B):85-9. PubMed ID: 3688012 [TBL] [Abstract][Full Text] [Related]
5. Effect of fibric acid derivatives on blood lipid and lipoprotein levels. Hunninghake DB; Peters JR Am J Med; 1987 Nov; 83(5B):44-9. PubMed ID: 3318453 [TBL] [Abstract][Full Text] [Related]
6. Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Brown WV; Dujovne CA; Farquhar JW; Feldman EB; Grundy SM; Knopp RH; Lasser NL; Mellies MJ; Palmer RH; Samuel P Arteriosclerosis; 1986; 6(6):670-8. PubMed ID: 3535757 [TBL] [Abstract][Full Text] [Related]
7. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. Bruckert E; De Gennes JL; Malbecq W; Baigts F Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530 [TBL] [Abstract][Full Text] [Related]
9. Effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia. Mellies MJ; Stein EA; Khoury P; Lamkin G; Glueck CJ Atherosclerosis; 1987 Jan; 63(1):57-64. PubMed ID: 3548734 [TBL] [Abstract][Full Text] [Related]
10. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study. Insua A; Massari F; Rodríguez Moncalvo JJ; Rubén Zanchetta J; Insua AM Endocr Pract; 2002; 8(2):96-101. PubMed ID: 11942772 [TBL] [Abstract][Full Text] [Related]
11. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Vega GL; Ma PT; Cater NB; Filipchuk N; Meguro S; Garcia-Garcia AB; Grundy SM Am J Cardiol; 2003 Apr; 91(8):956-60. PubMed ID: 12686335 [TBL] [Abstract][Full Text] [Related]
12. Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study. Goldberg AC; Schonfeld G; Feldman EB; Ginsberg HN; Hunninghake DB; Insull W; Knopp RH; Kwiterovich PO; Mellies MJ; Pickering J Clin Ther; 1989; 11(1):69-83. PubMed ID: 2655907 [TBL] [Abstract][Full Text] [Related]
13. Review of the effects of fenofibrate on lipoproteins, apoproteins, and bile saturation: US studies. Knopp RH Cardiology; 1989; 76 Suppl 1():14-22; discussion 29-32. PubMed ID: 2653621 [TBL] [Abstract][Full Text] [Related]
14. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262 [TBL] [Abstract][Full Text] [Related]
15. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia. Steinmetz A; Schwartz T; Hehnke U; Kaffarnik H J Cardiovasc Pharmacol; 1996 Apr; 27(4):563-70. PubMed ID: 8847874 [TBL] [Abstract][Full Text] [Related]
16. Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study. Sasaki J; Yamamoto K; Ageta M Clin Ther; 2002 Oct; 24(10):1614-26. PubMed ID: 12462290 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of a "suprabioavailable" formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials. Ramjattan BR; Callaghan DJ; Theiss U Clin Ther; 2002 Jul; 24(7):1105-16. PubMed ID: 12182255 [TBL] [Abstract][Full Text] [Related]
18. Correlation between plasma levels of fenofibrate and lipoprotein changes in hyperlipidaemic patients. Sirtori CR; Montanari G; Gianfranceschi G; Sirtori M; Galli G; Bosisio E Eur J Clin Pharmacol; 1985; 28(6):619-24. PubMed ID: 3840743 [TBL] [Abstract][Full Text] [Related]
19. Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs. Brown WV Cardiology; 1989; 76 Suppl 1():45-51; discussion 52-4. PubMed ID: 2653623 [TBL] [Abstract][Full Text] [Related]
20. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Adkins JC; Faulds D Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]